The Venture Codex Logo

The Venture Codex

Mehta Ventures

1841 W Demaret Centre, La Habra, California, 90631, United States

Overview

Mehta Ventures is an independent, privately-owned boutique family office that invests in early-stage startups and companies. The firm provides comprehensive startup, estate, and crypto co-investment opportunities to a trusted network of HNI families globally. The family has invested in 100+ companies through various platforms such as Angel List, Angel Networks, Incubators or co-investments with VCs. Mehta Ventures also provides capital, functional expertise, and the right connections to help early-stage ventures build, grow, and scale their business. They offer startups a strong entrepreneurial orientation in DNA or background or specific expertise and advice alongside patient capital.

Total investments
2
Lead investments
1
Investments · 12mo
0
Active investors
1

Sector focus

  • Finance
  • Financial Services
  • Venture Capital
Visit website

Investment portfolio

  • WorkClout

    Participated · Seed · Apr 2020

    WorkClout shifted its focus from manufacturing automation to manufacturing performance support after researching customer needs. The company built a tool that uses phones or tablets to guide workers through complex front-line tasks, provide feedback, and enable real-time communication between workers and management. Managers can monitor worker progress and communications on a back-end system, while workers can capture and share multimedia content to standardize training and reduce downtime. Founder Arjun Patel surveyed 124 manufacturers and concluded that employee training and engagement were primary pain points. To run lean during the pivot, WorkClout reduced headcount from nine to five employees. The company plans to hire again in Q4 or by Q1 next year and will use the new funding to build out the product and prepare for a go-to-market push. Financially, the business reports a runway of about 2.5 years at its current burn and revenue rates.

  • Retrotope

    Led · Series C · Jul 2019

    Retrotope, based in Los Altos, Calif., is developing a new category of patented, chemically stabilized compounds—D-PUFAs—aimed at preventing lipid peroxidation in mitochondrial and cellular membranes. Its lead compound, RT001, is an orally available D-PUFA designed to incorporate into membranes and protect against disease-induced excess lipid peroxidation. RT001 is being tested in clinical trials for Friedreich’s ataxia and Infantile Neuroaxonal Dystrophy, with expanded access studies underway in ALS, PSP Parkinsonism, GM1, late-onset Tay‑Sachs, Huntington’s disease and other disorders. The company has completed a blinded, randomized Phase 1/2 in Friedreich’s ataxia with post hoc statistical signals and has an ongoing pivotal trial in Infantile Neuroaxonal Dystrophy; a pivotal Friedreich’s ataxia trial was expected to start in Q3 2019. Retrotope reports over 250 patient‑months of drug safety exposure across clinical trial subjects and expanded access patients. The company is positioning its D-PUFA platform as a potential disease‑modifying approach for multiple neurodegenerative and retinopathy indications where lipid peroxidation is implicated.

Team